BLTE — Belite Bio, Inc
$154.74+2.97%
Last close: · regular session
Last 60 sessions
BLTE closed at $154.74 (+2.97%) on Oct 30, 2026. Active automatic shelf (F-3ASR, Oct 2025). Float: 18.5M shares. Latest SEC filing: 4 on Oct 31, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for BLTE in the TickerWise workspace.
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 25
- Website: https://belitebio.com
Latest SEC filings for BLTE
Latest BLTE news
- Belite Bio to uplist to Nasdaq Global Select Market Read article
- Belite Bio Announces Uplisting to the Nasdaq Global Select Market Read article
- Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.